TSWM
SUPN icon

Tyler-Stone Wealth Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Tyler-Stone Wealth Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-118
Closed -$3.16K – 871
2024
Q2 		$3.16K Buy
+118
New +$3.42K ﹤0.01% 811

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tyler-Stone Wealth Management's SUPN Position: Q3 2024 in Review

Tyler-Stone Wealth Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2024, closing a stake of 118 shares — an estimated $3.16K sold.

Tyler-Stone Wealth Management first reported a position in SUPN in Q2 2024 and held it in 1 quarter. The position peaked at $3.16K in Q2 2024. 273 funds tracked by Wall St. Rank hold SUPN as of Q3 2024.

  • Tyler-Stone Wealth Management reported no remaining Supernus Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Tyler-Stone Wealth Management sold 118 Supernus Pharmaceuticals shares in Q3 2024, an estimated $3.16K.
  • Tyler-Stone Wealth Management first reported a position in Supernus Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Tyler-Stone Wealth Management's Supernus Pharmaceuticals position peaked at $3.16K in Q2 2024.
  • 273 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2024.

Based on Tyler-Stone Wealth Management's 13F filing for Q3 2024, filed 4 Nov 2024.